In This Section      
 

Search Results

Title:
A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Monoclonal Antibody, and REGN2810, an Anti-programmed Death-1 Monoclonal Antibody, in Patients with B-cell Malignancies
Protocol Number:
J1607
Phase:
Phase I
Physician:
Nina Wagner-Johnston
Sites:
Johns Hopkins Kimmel Cancer Center in Baltimore
Purpose:
To evaluate the safety of REGN2810 and REGN1979 when given separately in subjects with Hodgkin’s lymphoma (HL), B-cell non-Hodgkin’s lymphoma (B-NHL), or B-cell acute lymphoblastic leukemia (B-ALL). This is a phase 1 study for dose escalation.
Eligibility:
Age 18+. Must have HL, B-NHL, or B-ALL that did not respond to most recent treatment or that relapsed after previous treatment. Patients with B-ALL must have received at least 1 cycle of induction and 1 cycle of consolidation chemotherapy.
Treatment:
Subjects will receive either study drug (REGN2810 or REGN1979) for a maximum of 48 weeks.
Population:
Adult
Last Update
03/05/2019 05:03 AM